# Nivolumab

## Opdivo inj 100mg/10mL

| 藥物代碼 | IOPD |
| :--- | :--- |
| 適應症 | Unresectable or Metastatic Melanoma. Adjuvant Treatment of Melanoma. Metastatic Non-Small Cell Lung Cancer. Advanced Renal Cell Carcinoma. Classical Hodgkin Lymphoma. Squamous Cell Carcinoma of the Head and Neck. Urothelial Carcinoma. Microsatellite Instability-High \(MSI-H\) or Mismatch Repair Deficient. Hepatocellular Carcinoma. |
| 副作用 | CommonHypertension \(36% \), Hand-foot syndrome due to cytotoxic therapy \(40% \), Pruritus \(10% to 53% \), Rash \(16% to 53% \), Hyperglycemia \(6% to 19% \), Abdominal pain \(10% to 34% \), Constipation \(10% or greater \), Decrease in appetite \(14% to 35% \), Nausea \(16% to 34% \), Stomatitis \(Up to 37% \), Vomiting \(12% to 31% \), Arthralgia \(10% to 23% \), Backache \(Renal cell carcinoma, 21% \), Musculoskeletal pain \(17% to 42% \), Headache \(11% to 23% \), Neuropathy \(Up to 12% \), Cough \(10% to 37% \), Dyspnea \(2% or greater \), Upper respiratory infection \(9% to 44% \), Fatigue \(12% or 62% \).SeriousMyocarditis, Pericarditis, Shock, Vasculitis, Erythroderma, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Adrenal insufficiency \(0.6% to 18% \), Diabetic ketoacidosis \(0.1% \), Hyperthyroidism \(2.7% to 12% \), Hypophysitis \(0.6% to 9% \), Hypopituitarism, Hypothyroidism \(4.5% to 34% \), Thyroiditis \(0.6% \), Type 1 diabetes mellitus \(0.9% \), Colitis \(1.9% to 26% \), Diarrhea \(17% to 64% \), Duodenitis, Esophageal fistula, Fatal \(0.5% \), Gastritis, Gastrointestinal hemorrhage, Fatal \(0.5% \), Pancreatitis, Perforation of colon \(Less than 10% \), Aplastic anemia, Autoimmune hemolytic anemia, Hemoptysis, Massive, Idiopathic thrombocytopenic purpura, Thrombocytopenia, Hepatitis \(1.8% to 21% \), Hepatotoxicity \(44% \), Veno-occlusive disease of the liver, Graft versus host disease, Histiocytic necrotizing lymphadenitis, Sarcoidosis, Transplanted organ rejection, Arthritis, Eaton-Lambert syndrome, Myasthenia gravis, Myositis, Polymyalgia rheumatica, Polymyositis, Rhabdomyolysis, Demyelination of spinal cord, Encephalitis, Guillain-Barre syndrome, Meningitis, Myelitis, Iritis, Myasthenia gravis, ocular, Unexplained visual loss, Uveitis \(0.8% \), Vogt-Koyanagi-Harada disease, Nephritis, Renal impairment, Urinary tract infectious disease \(Urothelial carcinoma, 17% \), Interstitial lung disease \(16% \), Pleural effusion \(2% or greater \), Pneumonia \(2% or greater \), Pneumonitis \(1.3% to 10% \), Pulmonary embolism \(Non-small cell lung cancer, recurrent, 4.2% \), Respiratory failure \(2% or greater \), Respiratory tract infection \(2% or greater \)Other: Cytomegalovirus infection, Disorder characterized by fever, Steroid-requiring, Sepsis \(2% or greater \) |
| 禁忌 | Specific contraindications have not been determined. |
| 藥物保存方式 | 冷藏於2-8℃,勿冷凍 |
| 用法用量 | Administer by intravenous infusion based upon recommended infusion rate for each indication. Unresectable or metastatic melanoma: 240 mg every 2 weeks or 480 mg every 4 weeks. 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. Adjuvant treatment of melanoma: 240 mg every 2 weeks or 480 mg every 4 weeks. Metastatic non-small cell lung cancer: 3 mg/kg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks. 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks and 2 cycles of platinum-doublet chemotherapy. 240 mg every 2 weeks or 480 mg every 4 weeks. Malignant pleural mesothelioma: 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks. Advanced renal cell carcinoma: 3 mg/kg followed by ipilimumab 1 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. 240 mg every 2 weeks or 480 mg every 4 weeks administered in combination with cabozantinib 40 mg once daily without food. 240 mg every 2 weeks or 480 mg every 4 weeks. Classical Hodgkin lymphoma: 240 mg every 2 weeks or 480 mg every 4 weeks. Recurrent or metastatic squamous cell carcinoma of the head and neck: 240 mg every 2 weeks or 480 mg every 4 weeks. Locally advanced or metastatic urothelial carcinoma: 240 mg every 2 weeks or 480 mg every 4 weeks. Microsatellite instability-high \(MSI-H\) or mismatch repair deficient: \(dMMR\) metastatic colorectal cancer. Adult and pediatric patients ? 40 kg: 240 mg every 2 weeks or 480 mg every 4 weeks. Pediatric patients &lt; 40 kg: 3 mg/kg every 2 weeks. Adult and pediatric patients ? 40 kg: 3 mg/kg followed by ipilimumab. 1 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. Hepatocellular carcinoma: 240 mg every 2 weeks or 480 mg every 4 weeks. 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. Esophageal squamous cell carcinoma: 240 mg every 2 weeks or 480 mg every 4 weeks. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | Contraindicated |
| 附帶說明 | \[仿單\]根據其作用機轉和動物試驗資料，當對孕婦投予 OPDIVO，可能會對胎兒造成傷害。在動物生殖研究中，對馬來猴從器官形成開始到生產期間投予 nivolumab，導致流產和早產胎兒死亡情形增加。 已知人類 IgG4 會通過胎盤障壁，nivolumab 亦為一種免疫球蛋白 G4 \(IgG4\)；因此，nivolumab 可能會從母體傳遞到發育中的胎兒。 OPDIVO 對第二及第三孕期的影響可能較大。目前尚無可說明此藥物相關風險的人類研究資料。應告知孕婦本品對胎兒的潛在風險。 目前不清楚對適用族群之重大先天缺陷和流產的背景風險；不過，在美國一般族群中，臨床上確認懷孕的背景風險分別是重大先天缺陷為 2%-4%，以及流產為 15%-20%。 PD-1/ PD-L1 途徑的一項核心作用為透過維持母體對胎兒的免疫耐受性來持續孕期。已在懷孕鼠模型證明，阻斷 PD-L1 信號會破壞對胎兒的耐受性並導致流產的增加。 從器官形成開始到生產期間，對猴子每週投予兩次 nivolumab \(其曝藥量比接受 nivolumab 3 mg/kg 臨床劑量所觀察到之曝藥量高出 9 至 42 倍\[根據血中濃度時間曲線下面積，AUC\]\)，以評估 nivolumab 對產前和產後發育的影響。 投予 nivolumab 會導致非劑量相關的自然流產和新生兒死亡增加。根據其作用機轉，胎兒暴露於 nivolumab 可能會使免疫調節性異常或正常免疫反應改變的風險增加，在 PD-1 基因剔除小鼠中曾發生免疫調節性異常。 接受nivolumab 治療的馬來猴存活子代中 \(32 隻中有 18 隻相較於未給藥組 16 隻有 11 隻\)，產後 6 個月期間並未出現明顯畸形且未對神經行為、免疫學和臨床病理學參數造成影響。 |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | \[仿單\]目前不清楚 OPDIVO 是否會分泌至人體乳汁中。 由於許多藥物\(包括抗體\)會分泌至人體乳汁中， 且因為OPDIVO 對接受哺乳的嬰兒可能造成嚴重不良反應， 建議孕婦在接受 OPDIVO 治療期間停止哺乳。 |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【D5W】 可選 仿單建議  【N/S】 可選 仿單建議 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | 抽取所需的OPDIVO容積，製備成最終濃度為1mg/mL至10mg/mL的輸注液。 對於體重≧30 kg 的病人給予 240 mg 或 360 mg 固定劑量\(flat-dose\)的總體積不得超過150mL 而體重&lt;30 kg 的病人給予之總體積不得超過100mL。 輕輕翻轉混合稀釋液。 請勿振搖輸液袋。 |
| 注意事項 | 1.從製備開始，置於室溫下的時間不得超過8小時。包括IV輸液袋內輸注液放置於室溫下2.透過含無菌、無熱原、低蛋白結合率過濾器\(孔徑大小為0.2微米至1.2微米\)的靜脈導管連續輸注30分鐘 3.請勿以相同的靜脈導管同時輸注其他藥物。輸注結束後應沖洗靜脈導管 4.併用ipilimumab時，同一天先給予OPDIVO後再給予ipilimumab。當併用ipilimumab和化學治療時，同一天應先給予OPDIVO接著給予ipilimumab，最後再給予化學治療 5.應使用個別的輸液袋和過濾器 |

